ALKS Stock Overview
A biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Alkermes plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$30.13 |
| 52 Week High | US$36.45 |
| 52 Week Low | US$22.90 |
| Beta | 0.47 |
| 1 Month Change | 4.58% |
| 3 Month Change | -4.56% |
| 1 Year Change | 25.28% |
| 3 Year Change | 12.09% |
| 5 Year Change | 97.32% |
| Change since IPO | 447.82% |
Recent News & Updates
Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial Possible
May 01Alkermes plc's (NASDAQ:ALKS) Earnings Are Not Doing Enough For Some Investors
Apr 21
Recent updates
Alkermes: Label Expansion Of LYBALVI With Ongoing Pediatric Trial Possible
May 01Alkermes plc's (NASDAQ:ALKS) Earnings Are Not Doing Enough For Some Investors
Apr 21Alkermes' Neuroscience Pivot: ALKS 2680 Set To Revolutionize Narcolepsy Treatment
Feb 25Benign Growth For Alkermes plc (NASDAQ:ALKS) Underpins Its Share Price
Jan 16We Think Alkermes (NASDAQ:ALKS) Can Stay On Top Of Its Debt
Dec 17Alkermes: Products Sales, ALKS 2680 Can Still Drive Long-Term Growth
Nov 24Alkermes plc's (NASDAQ:ALKS) Low P/E No Reason For Excitement
Oct 14Is Alkermes (NASDAQ:ALKS) A Risky Investment?
Sep 17
Robust Product Demand And Critical Innovations Set To Propel Growth, Amid Analysts' Concerns And Revenue Diversification Challenges
Aug 31 Proprietary products and strategic sales like the Athlone facility sale signal robust revenue growth and operational efficiency, showing promise for future earnings.Alkermes: Fairly Valued After Post-Earnings Bump
Jul 28Does Alkermes (NASDAQ:ALKS) Deserve A Spot On Your Watchlist?
Jul 26Alkermes plc's (NASDAQ:ALKS) Business And Shares Still Trailing The Industry
Jul 04The Bottom Fishing Club: Alkermes Has Great Value And Safety
May 17Alkermes: Waking Up Narcolepsy Treatment With Promising Trial Data
Apr 09Alkermes: Slimmed-Down Pharma Not A Compelling Growth Story Yet
Jan 26Alkermes upgraded to neutral at BofA on improved risk/reward outlook
Oct 14Alkermes holder Sarissa Capital says it may look to increase its stake
Oct 07Alkermes: Nothing Stands Out As Interesting
Sep 26Alkermes initiated at neutral at Piper Sandler as company in transition
Aug 16Alkermes Q2 2022 Earnings Preview
Jul 26Shareholder Returns
| ALKS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.2% | -9.0% | -0.3% |
| 1Y | 25.3% | -15.2% | 8.0% |
Return vs Industry: ALKS exceeded the US Biotechs industry which returned -13.2% over the past year.
Return vs Market: ALKS exceeded the US Market which returned 8.2% over the past year.
Price Volatility
| ALKS volatility | |
|---|---|
| ALKS Average Weekly Movement | 5.5% |
| Biotechs Industry Average Movement | 11.9% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: ALKS has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ALKS's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 1,800 | Richard Pops | www.alkermes.com |
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder.
Alkermes plc Fundamentals Summary
| ALKS fundamental statistics | |
|---|---|
| Market cap | US$5.01b |
| Earnings (TTM) | US$355.65m |
| Revenue (TTM) | US$1.51b |
14.0x
P/E Ratio3.3x
P/S RatioIs ALKS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALKS income statement (TTM) | |
|---|---|
| Revenue | US$1.51b |
| Cost of Revenue | US$235.88m |
| Gross Profit | US$1.28b |
| Other Expenses | US$922.23m |
| Earnings | US$355.65m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 2.16 |
| Gross Margin | 84.42% |
| Net Profit Margin | 23.49% |
| Debt/Equity Ratio | 0% |
How did ALKS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/09 06:41 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Alkermes plc is covered by 35 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joel Beatty | Baird |
| Robert Hazlett | BMO Capital Markets U.S. (Historical) |
| Jason Matthew Gerberry | BofA Global Research |